ArticleCureus2025
Remission Induced by Shichimotsukokato in an Older Adult With Nephrotic Syndrome Secondary to Diabetic Kidney Disease: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrotic syndrome is a major renal disease characterized by massive proteinuria, hypoalbuminemia, systemic edema, and hyperlipidemia. Diabetic kidney disease (DKD) can induce secondary nephrotic syndrome, which is often challenging to manage with conventional treatments such as renin-angiotensin system inhibitors and diuretics. We present a case of a 90-year-old woman with DKD who developed nephrotic syndrome secondary to DKD that was refractory to standard treatments. Upon administration of shichimotsukokato (SCMKT), a representative Kampo formula created in Japan, there was a marked reduction in the proteinuria and an improvement in the serum albumin concentration, leading to remission of the nephrotic syndrome and enabling tapering of the renin-angiotensin system inhibitor and diuretics. This case suggests that SCMKT may be a candidate therapeutic option for nephrotic syndrome in patients with DKD. Further studies are needed to clarify the clinical benefits and pharmacological mechanisms of SCMKT in DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.